Literature DB >> 5116208

A decreased metabolic clearance rate of aldosterone in benign essential hypertension.

W Nowaczynski, O Kuchel, J Genest.   

Abstract

Aldosterone secretion rate, metabolic clearance rate, and/or plasma concentration were determined in 16 patients with benign, uncomplicated essential hypertension and compared with those of control subjects. The mean metabolic clearance rate of aldosterone in 10 patients was significantly (P < 0.001) lower (mean 867 liters of plasma/day per m(2) +/-270 SD) than in a group of 7 healthy subjects (mean 1480 liters/day per m(2) +/-265 SD). Secretion rates in 13 patients (including the 10 already mentioned) tended to be low (83 +/-43 vs. 109 +/-54 mug/day) and plasma concentrations tended to be high (13.6 +/-4.6 vs. 7.5 +/-4.8 ng/100 ml), but neither of these differences was statistically significant. The lower metabolic clearance rate could account for elevated plasma concentrations of aldosterone even when the secretion rate is normal or low. Measurement of secretion rate or urinary excretion only is therefore insufficient to establish the presence and/or mode of evolution of hyperaldosteronism. Failure of the aldosterone secretion to adapt fully to a decreased aldosterone metabolic clearance rate (MCR) could explain the state of relative hyperaldosteronism in patients with benign essential hypertension, even when the secretion rate and the urinary excretion rate are in the normal range.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5116208      PMCID: PMC292153          DOI: 10.1172/JCI106713

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  ALDOSTERONE SECRETION AND VARIOUS FORMS OF HYPERTENSIVE VASCULAR DISEASE.

Authors:  J H LARAGH; P J CANNON; R P AMES
Journal:  Ann Intern Med       Date:  1963-07       Impact factor: 25.391

2.  NORMAL AND ALTERED FUNCTION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN MAN: APPLICATIONS IN CLINICAL AND RESEARCH MEDICINE.

Authors:  J W CONN; D R ROVNER; E L COHEN
Journal:  Ann Intern Med       Date:  1965-08       Impact factor: 25.391

3.  Essential hypertension and aldosterone.

Authors:  E H VENNING; I DYRENFURTH; J B DOSSETOR; J C BECK
Journal:  Circulation       Date:  1961-02       Impact factor: 29.690

4.  The effect of estrogen administration on the metabolism and protein binding of hydrocortisone.

Authors:  I H MILLS; H P SCHEDL; P S CHEN; F C BARTTER
Journal:  J Clin Endocrinol Metab       Date:  1960-04       Impact factor: 5.958

5.  Electrolyte metabolism and aldosterone secretion in benign and malignant hypertension.

Authors:  J H LARAGH; S ULICK; V JANUSZEWICZ; W G KELLY; S LIEBERMAN
Journal:  Ann Intern Med       Date:  1960-08       Impact factor: 25.391

6.  NEW PROCEDURES FOR MEASUREMENT OF HUMAN PLASMA ANGIOTENSIN AND RENIN ACTIVITY LEVELS.

Authors:  R BOUCHER; R VEYRAT; J DE CHAMPLAIN; J GENEST
Journal:  Can Med Assoc J       Date:  1964-01-25       Impact factor: 8.262

7.  [Not Available].

Authors:  F TRONCHETTI; G MUCIO; R ROMANELLI
Journal:  Ann Endocrinol (Paris)       Date:  1957 Jul-Aug       Impact factor: 2.478

8.  Human arterial hypertension: a state of mild chronic hyperaldosteronism?

Authors:  J GENEST; G LEMIEUX; A DAVIGNON; E KOIW; W NOWACZYNSKI; P STEYERMARK
Journal:  Science       Date:  1956-03-23       Impact factor: 47.728

9.  Metabolic studies on hypertensive patients with suppressed plasma renin activity not due to hyperaldosternosm.

Authors:  O M Helmer; W E Judson
Journal:  Circulation       Date:  1968-11       Impact factor: 29.690

View more
  4 in total

1.  Jeremiah Metzger lecture, 1974: The renin-angiotensin system. Some new aspects.

Authors:  J Genest; R Boucher; O Kuchel; J M Rojo-Ortega; W Nowaczynski
Journal:  Trans Am Clin Climatol Assoc       Date:  1975

2.  New evidences of disturbances of mineralocorticoid activity in benign, uncomplicated essential hypertension.

Authors:  J Genest; W J Nowaczynski; O Küchel; C Sasaki
Journal:  Trans Am Clin Climatol Assoc       Date:  1972

Review 3.  Aldosterone and renin in essential hypertension.

Authors:  J Genest; W Nowaczynski; R Boucher; O Kuchel; J M Rojo-Ortega
Journal:  Can Med Assoc J       Date:  1975-09-06       Impact factor: 8.262

Review 4.  Role of the adrenal cortex and sodium in the pathogenesis of human hypertension.

Authors:  J Genest; W Nowaczynski; R Boucher; O Kuchel
Journal:  Can Med Assoc J       Date:  1978-03-04       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.